Filtros de búsqueda

Lista de obras de Tawanda Gumbo

A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease

artículo científico publicado en 2017

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground

artículo científico publicado en 2016

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.

artículo científico publicado en 2016

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies

artículo científico publicado en 2016

A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients

artículo científico publicado en 2013

A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs

artículo científico publicado en 2011

A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease

artículo científico publicado en 2017

A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting

artículo científico publicado en 2017

AIDS Orphans

article

Acquired Drug Resistance Because of Pharmacokinetic Variability in a Young Child With Tuberculosis

scholarly article by Jotam G. Pasipanodya et al published November 2014 in Pediatric Infectious Disease Journal

Acquired Drug Resistance: We Can Do More Than We Think!

artículo científico publicado en 2014

Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients

artículo científico publicado en 2015

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis

artículo científico publicado en 2016

An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future

artículo científico publicado en 2010

Anidulafungin in the treatment of invasive fungal infections

artículo científico publicado en 2008

Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis

artículo científico publicado en 2006

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis

artículo científico publicado en 2017

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

scientific article published in 2007

Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.

scientific article published on 25 July 2016

Artificial intelligence–derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis

scholarly article by Jotam G Pasipanodya et al published 28 November 2018 in Clinical Infectious Diseases

Aspergillus valve endocarditis in patients without prior cardiac surgery.

artículo científico publicado en 2000

Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease

artículo científico publicado en 2016

Biological variability and the emergence of multidrug-resistant tuberculosis

artículo científico publicado en 2013

Candida glabrata Fungemia. Clinical features of 139 patients

artículo científico publicado en 1999

Candida(Torulopsis)glabrataSeptic Arthritis

scientific article published in 1999

Case report. Nattrassia mangiferae endophthalmitis

artículo científico publicado en 2002

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

artículo científico publicado en 2017

Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used

artículo científico publicado en 2010

Clinicopathological features of cutaneous histoplasmosis in human immunodeficiency virus-infected patients in Zimbabwe

artículo científico publicado en 2001

Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study

scholarly article by J. G. Pasipanodya et al published 1 September 2014 in Journal of Antimicrobial Chemotherapy

Comparison of a novel regimen of rifapentine, tedizolid, and minocycline with standard regimens for treatment of the pulmonary Mycobacterium kansasii

artículo científico publicado en 2020

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis

artículo científico publicado en 2017

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.

artículo científico publicado en 2016

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

artículo científico publicado en 2007

Confirmation of transmission of Enterocytozoon bieneusi in South Africa

article

Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm

artículo científico publicado en 2015

Cryptococcus myelitis: Atypical Presentation of a Common Infection

scientific article published in 2001

Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome

artículo científico publicado en 2002

Cyclospora: update on an emerging pathogen

artículo científico publicado en 1997

Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study.

artículo científico publicado en 2019

Development and application of genetic probes for detection of Enterocytozoon bieneusi in formalin-fixed stools and in intestinal biopsy specimens from infected patients

artículo científico publicado en 1997

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests

artículo científico publicado en 2016

Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusions

artículo científico publicado en 2013

Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis

scientific article published on 01 November 2018

Dysentery in patients infected with human immunodeficiency virus in Zimbabwe: an emerging role for Schistosoma mansoni and Escherichia coli O157?

artículo científico publicado en 2001

Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients

artículo científico publicado en 2021

Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!

artículo científico publicado en 2018

Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol

artículo científico publicado en 2010

Enterocytozoon bieneusi infection in patients without evidence of immunosuppression: two cases from Zimbabwe found to have positive stools by PCR.

artículo científico publicado en 2000

Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium

artículo científico publicado en 2010

Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people

artículo científico publicado en 2011

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis

scholarly article by Devyani Deshpande et al published 28 November 2018 in Clinical Infectious Diseases

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection

artículo científico publicado en 2016

Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance

artículo científico publicado en 2017

Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis

scholarly article by J. Pasipanodya et al published 3 February 2015 in Journal of Infectious Diseases

Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes

artículo científico publicado en 2015

Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People

artículo científico publicado en 2016

Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people

artículo científico publicado en 2011

Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis

artículo científico publicado en 2014

Glucan Synthase Inhibitors

scholarly article

Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis

artículo científico publicado en 2014

Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies

artículo científico publicado en 2007

In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens ⬇️

artículo científico publicado el 1 de enero de 2011

In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis

artículo científico publicado en 2010

In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos

article

In vitro susceptibility testing and totally drug-resistant tuberculosis

artículo científico publicado en 2013

Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?

scholarly article by Jotam G Pasipanodya & Tawanda Gumbo published 3 March 2018 in Clinical Infectious Diseases

Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosis

artículo científico publicado en 2014

Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose Rifampicin, Isoniazid and Pyrazinamide Treatment in multidrug-resistant tuberculosis Programmes.

artículo científico publicado en 2018

Intestinal parasites in patients with diarrhea and human immunodeficiency virus infection in Zimbabwe

artículo científico publicado en 1999

Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations

artículo científico publicado en 2007

Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation

artículo científico publicado en 2016

Isoniazid’s Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion ofMycobacterium tuberculosisin the Log Phase of Growth

artículo científico publicado en 2007

Late Complications of Candida (Torulopsis) glabrata Fungemia: Description of a Phenomenon

artículo científico publicado en 2002

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis

artículo científico publicado en 2017

Linezolid as treatment for pulmonary Mycobacterium avium disease

artículo científico publicado en 2017

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps

artículo científico publicado en 2016

Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.

artículo científico publicado en 2017

Meningeal Tuberculosis

scholarly article by Joanna E. T. Shaw et al published May 2010 in Medicine

Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease

artículo científico publicado en 2017

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy

artículo científico publicado en 2012

Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models

artículo científico publicado en 2019

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

artículo científico publicado en 2014

Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection

artículo científico publicado en 2010

Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease

artículo científico publicado en 2016

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

artículo científico publicado en 2011

Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science.

artículo científico publicado en 2017

Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis

article

Mycobacterial shuttle vectors designed for high-level protein expression in infected macrophages

artículo científico publicado en 2012

New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates

artículo científico publicado en 2012

New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability

artículo científico publicado en 2010

Nonclinical models for antituberculosis drug development: a landscape analysis

artículo científico

Once-a-week tigecycline for the treatment of drug-resistant TB

artículo científico publicado en 2019

Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia

artículo científico publicado en 2006

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks

artículo científico publicado en 2016

Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study

artículo científico publicado en 2017

Pan-tuberculosis regimens: an argument against.

artículo científico publicado en 2018

Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead

artículo científico publicado en 2016

Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection

artículo científico publicado en 2012

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance

artículo científico publicado en 2005

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity

artículo científico publicado en 2005

Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling

artículo científico publicado en 2011

Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia

artículo científico

Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs

article

Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium

artículo científico publicado en 2011

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs

artículo científico publicado en 2009

Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis

artículo científico publicado en 2015

Population pharmacokinetics of cycloserine, and pharmacokinetic/pharmacodynamic target attainment, in MDR-tuberculosis patients dosed with terizidone

artículo científico publicado en 2020

Population pharmacokinetics of micafungin in adult patients

artículo científico publicado en 2007

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing

artículo científico publicado en 2007

Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.

artículo científico publicado en 2017

Quantification of echodensities in tuberculous pericardial effusion using fractal geometry: a proof of concept study

artículo científico publicado en 2012

Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease

artículo científico publicado en 2015

Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy

artículo científico publicado en 2014

Reply to "breakpoints and drug exposure are inevitably closely linked"

artículo científico publicado en 2015

Reply to Moonan and Weis, Seaworth et al, and Nunn and Phillips

artículo científico publicado en 2013

Reply to Wallis et al. and Mitchison et al

artículo científico publicado en 2007

Reply to Zimenkov, "Mutation in luxR Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance".

artículo científico publicado en 2018

Reply to “Pharmacokinetic Mismatch of Tuberculosis Drugs”.

artículo científico publicado en 2012

Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill

artículo científico publicado en 2020

Scientific and patient care evidence to change susceptibility breakpoints for first-line anti-tuberculosis drugs [Correspondence]

article

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling

artículo científico publicado en 2004

Serum drug concentrations predictive of pulmonary tuberculosis outcomes

artículo científico publicado en 2013

Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!

artículo científico publicado en 2015

Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing

artículo científico publicado en 2019

Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.

artículo científico publicado en 2018

Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing

artículo científico publicado en 2017

Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study

artículo científico publicado en 2014

Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations

artículo científico publicado en 2017

Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis

artículo científico publicado en 2016

Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments

artículo científico publicado en 2015

Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence

artículo científico publicado en 2017

Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease

artículo científico publicado en 2017

The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism

artículo científico publicado en 2016

The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis

scholarly article by Shashikant Srivastava et al published 28 November 2018 in Clinical Infectious Diseases

The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance

artículo científico publicado en 2012

The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations

artículo científico publicado en 2006

The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent

artículo científico publicado en 2017

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

artículo científico publicado en 2017

The pyrazinamide susceptibility breakpoint above which combination therapy fails

artículo científico publicado en 2014

Therapy duration and long-term outcomes in extra-pulmonary tuberculosis

artículo científico publicado en 2014

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases

artículo científico publicado en 2016

Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners

scientific article published on 16 September 2013

Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease

artículo científico publicado en 2016

Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges

artículo científico publicado en 2018

Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

artículo científico publicado en 2009

Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High Mortality

artículo científico publicado en 2015

Urine Colorimetry for Therapeutic Drug Monitoring of Pyrazinamide during Tuberculosis Treatment

artículo científico publicado en 2017

Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study

artículo científico publicado en 2016

Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths

artículo científico publicado en 2013

Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis

artículo científico publicado en 2011

pH Conditions under Which Pyrazinamide Works in Humans.

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda